At a glance

ClinicalIndex Comparison Record

N/ACompleted· 30 enrolled

Drug / intervention

Tocilizumab Injectable Product +1 moredrug

Likely dose

Saline 0.9% 100 ml NaCl 0.9% will be infused over 1 hourfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04616235

NCT04616235N/ACompleted

Compare CT.gov

Acute Exercise and NK Cell Regulation in Tissue and Circulation After IL-6R Blockade - a Randomized Controlled Trial

Rigshospitalet, Denmark·interventional·Posted Nov 4, 2020·Updated Aug 22, 2022

In Brief

A clinical study evaluating Tocilizumab Injectable Product and Saline 0.9% 100 ml NaCl 0.9% will be infused over 1 hour for Interleukin-6 Inhibition and 2 related conditions. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The study is a randomized controlled trial studying the acute effect of intense aerobic exercise upon NK (Natural Killer) cell activation and appetite-regulation in human participants with or without concommitant IL-6R receptor blockade (Tocilizumab)

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsInterleukin-6 Inhibition, Physical Stress, Appetitive Behavior

CountriesDenmark

Collaborators--

Timeline

N/ACompletedFinished

202120222023202420252026

First PostedNov 2020

Enrollment StartMar 2021

Primary CompletionOct 2021

TodayJul 2026

First PostedNov 4, 2020

Enrollment StartMar 15, 2021

Primary CompletionOct 4, 2021

TodayJul 2, 2026

Enrollment to primary: 7 monthsPosted 5.7 years ago

Interventions

Tocilizumab Injectable Productdrug

The intervention group will undergo intense aerobic exercise with prior IL-6R infusion for 1h prior to the exercise bout.

Saline 0.9% 100 ml NaCl 0.9% will be infused over 1 hourother

The control group will undergo intense aerobic exercise with saline infusion for 1h prior to the exercise bout